Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Hologic authorizes $1B share repurchase program » 16:22
09/23/22
09/23
16:22
09/23/22
16:22
HOLX

Hologic

$62.99 /

+0.19 (+0.30%)

In a regulatory filing,…

In a regulatory filing, on September 22, 2022, the board of directors of Hologic authorized a new stock repurchase program, with a five-year term, to repurchase up to $1B of the company's outstanding common stock, effective as of the close of trading on the NASDAQ Stock Market LLC on September 23, 2022. This new stock repurchase authorization replaces the previous $1B authorization, which had approximately $150M remaining as of September 22, 2022.

ShowHide Related Items >><<
HOLX Hologic
$62.99 /

+0.19 (+0.30%)

HOLX Hologic
$62.99 /

+0.19 (+0.30%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
HOLX Hologic
$62.99 /

+0.19 (+0.30%)

HOLX Hologic
$62.99 /

+0.19 (+0.30%)

Conference/Events
Wells Fargo to hold a conference » 04:55
09/09/22
09/09
04:55
09/09/22
04:55
ABBV

AbbVie

$140.52 /

+1.48 (+1.06%)

, AVEO

Aveo Pharmaceuticals

$8.59 /

+0.28 (+3.37%)

, BNFT

Benefitfocus

$6.92 /

-0.13 (-1.84%)

, DGX

Quest Diagnostics

$130.17 /

+2.86 (+2.25%)

, FATE

Fate Therapeutics

$28.25 /

+0.935 (+3.42%)

, INSP

Inspire Medical

$197.41 /

+8.2 (+4.33%)

, LEGN

Legend Biotech

$43.61 /

-0.25 (-0.57%)

, GILD

Gilead

$65.11 /

+0.325 (+0.50%)

, HOLX

Hologic

$68.88 /

+1.17 (+1.73%)

, INGN

Inogen

$27.44 /

-0.75 (-2.66%)

, KYMR

Kymera Therapeutics

$28.76 /

+0.27 (+0.95%)

, NOTV

Inotiv

$21.74 /

+0.68 (+3.23%)

, PEN

Penumbra

$197.58 /

+11.9 (+6.41%)

, RGLS

Regulus

$1.61 /

+0.04 (+2.55%)

, SWAV

ShockWave Medical

$292.67 /

+4.85 (+1.69%)

, WAT

Waters

$308.63 /

+6.55 (+2.17%)

, SUPN

Supernus

$34.53 /

+0.34 (+0.99%)

, ORIC

Oric Pharmaceuticals

$3.56 /

+0.12 (+3.49%)

, PGEN

Precigen

$2.46 /

+0.145 (+6.28%)

, NRIX

Nurix Therapeutics

$15.99 /

-0.13 (-0.81%)

, NUVA

NuVasive

$46.21 /

+0.89 (+1.96%)

, AUTL

Autolus Therapeutics

$3.12 /

+0.19 (+6.48%)

, HALO

Halozyme

$39.63 /

+0.25 (+0.63%)

, IMVT

Immunovant

$5.06 /

+0.145 (+2.95%)

, JNCE

Jounce Therapeutics

$3.49 /

-0.06 (-1.69%)

, IDYA

Ideaya Biosciences

$9.31 /

+0.01 (+0.11%)

, SYK

Stryker

$220.34 /

+9.14 (+4.33%)

, NPCE

NeuroPace

$4.50 /

-0.275 (-5.77%)

, IONS

Ionis Pharmaceuticals

$44.28 /

+0.9 (+2.07%)

, HRMY

Harmony Biosciences

$47.66 /

+1.675 (+3.64%)

2022 Wells Fargo…

2022 Wells Fargo Healthcare Conference to be held in Everett, MA on September 7-9.

ShowHide Related Items >><<
SYK Stryker
$220.34 /

+9.14 (+4.33%)

SWAV ShockWave Medical
$292.67 /

+4.85 (+1.69%)

SUPN Supernus
$34.53 /

+0.34 (+0.99%)

RGLS Regulus
$1.61 /

+0.04 (+2.55%)

PGEN Precigen
$2.46 /

+0.145 (+6.28%)

ORIC Oric Pharmaceuticals
$3.56 /

+0.12 (+3.49%)

NUVA NuVasive
$46.21 /

+0.89 (+1.96%)

NRIX Nurix Therapeutics
$15.99 /

-0.13 (-0.81%)

NPCE NeuroPace
$4.50 /

-0.275 (-5.77%)

NOTV Inotiv
$21.74 /

+0.68 (+3.23%)

LEGN Legend Biotech
$43.61 /

-0.25 (-0.57%)

KYMR Kymera Therapeutics
$28.76 /

+0.27 (+0.95%)

JNCE Jounce Therapeutics
$3.49 /

-0.06 (-1.69%)

IONS Ionis Pharmaceuticals
$44.28 /

+0.9 (+2.07%)

INSP Inspire Medical
$197.41 /

+8.2 (+4.33%)

IMVT Immunovant
$5.06 /

+0.145 (+2.95%)

IDYA Ideaya Biosciences
$9.31 /

+0.01 (+0.11%)

HRMY Harmony Biosciences
$47.66 /

+1.675 (+3.64%)

HOLX Hologic
$68.88 /

+1.17 (+1.73%)

HALO Halozyme
$39.63 /

+0.25 (+0.63%)

GILD Gilead
$65.11 /

+0.325 (+0.50%)

FATE Fate Therapeutics
$28.25 /

+0.935 (+3.42%)

DGX Quest Diagnostics
$130.17 /

+2.86 (+2.25%)

BNFT Benefitfocus
$6.92 /

-0.13 (-1.84%)

AVEO Aveo Pharmaceuticals
$8.59 /

+0.28 (+3.37%)

AUTL Autolus Therapeutics
$3.12 /

+0.19 (+6.48%)

ABBV AbbVie
$140.52 /

+1.48 (+1.06%)

ABBV AbbVie
$140.52 /

+1.48 (+1.06%)

08/30/22 Piper Sandler
I-Mab price target lowered to $30 from $35 at Piper Sandler
08/24/22 Argus
AbbVie price target lowered to $155 from $165 at Argus
08/01/22 JPMorgan
AbbVie selloff Friday a buying opportunity, says JPMorgan
08/01/22 Barclays
AbbVie price target lowered to $160 from $174 at Barclays
AVEO Aveo Pharmaceuticals
$8.59 /

+0.28 (+3.37%)

03/14/22 JonesTrading
Aveo Pharmaceuticals initiated with a Buy at JonesTrading
BNFT Benefitfocus
$6.92 /

-0.13 (-1.84%)

09/06/22 Piper Sandler
Benefitfocus price target lowered to $6 from $9 at Piper Sandler
06/22/22 Piper Sandler
Benefitfocus downgraded to Neutral from Overweight at Piper Sandler
DGX Quest Diagnostics
$130.17 /

+2.86 (+2.25%)

08/22/22 Morgan Stanley
Quest Diagnostics assumed with an Equal Weight at Morgan Stanley
07/22/22 Mizuho
Quest Diagnostics price target lowered to $160 from $185 at Mizuho
07/22/22 Credit Suisse
Quest Diagnostics price target lowered to $143 from $158 at Credit Suisse
04/24/22 UBS
Quest Diagnostics price target raised to $150 from $139 at UBS
FATE Fate Therapeutics
$28.25 /

+0.935 (+3.42%)

08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
08/04/22 Oppenheimer
Fate Therapeutics price target lowered to $90 from $135 at Oppenheimer
07/28/22 Needham
Fate Therapeutics initiated with a Hold at Needham
07/11/22 BMO Capital
Fate Therapeutics upgraded to Outperform from Market Perform at BMO Capital
INSP Inspire Medical
$197.41 /

+8.2 (+4.33%)

08/03/22 Truist
Inspire Medical price target raised to $280 from $250 at Truist
08/03/22 Piper Sandler
Inspire Medical price target lowered to $285 from $310 at Piper Sandler
07/05/22 Piper Sandler
Piper says Inspire appears to have received FDA approval for expanded labeling
06/10/22 Truist
Inspire Medical price target lowered to $250 from $296 at Truist
LEGN Legend Biotech
$43.61 /

-0.25 (-0.57%)

07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
06/16/22 BMO Capital
Legend Biotech initiated with an Outperform at BMO Capital
05/31/22 Morgan Stanley
Legend Biotech named Catalyst Driven Idea by Morgan Stanley
03/15/22 Barclays
Legend Biotech initiated with an Overweight at Barclays
GILD Gilead
$65.11 /

+0.325 (+0.50%)

09/02/22 Argus
Gilead pullback provides favorable entry point, says Argus
08/15/22 Piper Sandler
Gilead's Trodelvy shows OS benefit in HR+/HER- BC, says Piper Sandler
08/15/22 Piper Sandler
Gilead price target raised to $74 from $71 at Piper Sandler
08/08/22 Truist
Gilead price target lowered to $71 from $75 at Truist
HOLX Hologic
$68.88 /

+1.17 (+1.73%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
INGN Inogen
$27.44 /

-0.75 (-2.66%)

05/09/22 Stifel
Inogen price target lowered to $30 from $40 at Stifel
12/09/21 Needham
Inogen upgraded to Buy from Hold at Needham
12/09/21 Needham
Inogen upgraded to Buy from Hold at Needham
11/02/21
Fly Intel: Top five analyst upgrades
KYMR Kymera Therapeutics
$28.76 /

+0.27 (+0.95%)

08/31/22 JPMorgan
Kymera selloff a 'misplaced knee-jerk reaction,' says JPMorgan
08/15/22 Jefferies
Kymera Therapeutics initiated with a Buy at Jefferies
08/03/22 Goldman Sachs
Kymera Therapeutics initiated with a Buy at Goldman Sachs
07/20/22 SVB Securities
Kymera Therapeutics initiated with a Market Perform at SVB Securities
NOTV Inotiv
$21.74 /

+0.68 (+3.23%)

08/11/22 Lake Street
Inotiv price target raised to $60 from $50 at Lake Street
06/14/22 Lake Street
Inotiv price target lowered to $50 from $75 at Lake Street
02/11/22 Lake Street
Inotiv price target raised to $75 from $60 at Lake Street
02/02/22 Craig-Hallum
Inotiv price target raised to $64 from $57 at Craig-Hallum
PEN Penumbra
$197.58 /

+11.9 (+6.41%)

08/05/22 Canaccord
Penumbra price target lowered to $189 from $244 at Canaccord
07/21/22 Deutsche Bank
Penumbra price target lowered to $163 from $250 at Deutsche Bank
07/18/22 BTIG
Penumbra price target lowered to $213 from $272 at BTIG
07/18/22 RBC Capital
Penumbra initiated with an Outperform at RBC Capital
RGLS Regulus
$1.61 /

+0.04 (+2.55%)

SWAV ShockWave Medical
$292.67 /

+4.85 (+1.69%)

09/06/22 Oppenheimer
Oppenheimer downgrades ShockWave Medical to Underperform with $165 price target
09/06/22 Oppenheimer
ShockWave Medical downgraded to Underperform from Perform at Oppenheimer
08/29/22 Piper Sandler
ShockWave Medical price target raised to $338 from $278 at Piper Sandler
08/09/22 Canaccord
ShockWave Medical price target raised to $256 from $232 at Canaccord
WAT Waters
$308.63 /

+6.55 (+2.17%)

08/24/22 Credit Suisse
Waters initiated with a Neutral at Credit Suisse
08/03/22 Baird
Waters price target raised to $348 from $340 at Baird
07/20/22 UBS
Waters initiated with a Neutral at UBS
07/05/22 Evercore ISI
Waters added to 'Tactical Outperform' list at Evercore ISI
SUPN Supernus
$34.53 /

+0.34 (+0.99%)

08/31/22 Piper Sandler
Supernus price target raised to $38 from $33 at Piper Sandler
12/01/21 Jefferies
Supernus resumed with a Buy at Jefferies
10/12/21 JMP Securities
Adamas Pharmaceuticals cut to Market Perform from Outperform at JMP Securities
10/12/21 H.C. Wainwright
Adamas Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
ORIC Oric Pharmaceuticals
$3.56 /

+0.12 (+3.49%)

07/15/22 Oppenheimer
Oric Pharmaceuticals assumed with a Perform at Oppenheimer
04/04/22 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/22 H.C. Wainwright
Oric Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
03/22/22 Guggenheim
Oric downgraded to Neutral at Guggenheim after ORIC-101 discontinuation
PGEN Precigen
$2.46 /

+0.145 (+6.28%)

08/09/22 H.C. Wainwright
Precigen price target lowered to $6 from $10 at H.C. Wainwright
07/05/22 Stifel
Precigen subsidiary sale relieves convertible debt overhang, says Stifel
NRIX Nurix Therapeutics
$15.99 /

-0.13 (-0.81%)

07/11/22 H.C. Wainwright
Nurix Therapeutics price target lowered to $54 from $60 at H.C. Wainwright
07/08/22 Stifel
Nurix Therapeutics price target lowered to $37 from $44 at Stifel
07/08/22 JPMorgan
Nurix Therapeutics price target lowered to $37 from $46 at JPMorgan
07/08/22 Baird
Nurix Therapeutics price target lowered to $32 from $41 at Baird
NUVA NuVasive
$46.21 /

+0.89 (+1.96%)

08/23/22 Piper Sandler
NuVasive selloff on bus tour comments an opportunity, says Piper Sandler
08/04/22 Canaccord
NuVasive price target raised to $55 from $50 at Canaccord
08/04/22 Piper Sandler
NuVasive price target lowered to $60 from $80 at Piper Sandler
06/28/22 Stifel
Stifel cuts Orthofix target, says momentum 'faded' during Q2
AUTL Autolus Therapeutics
$3.12 /

+0.19 (+6.48%)

06/14/22 Truist
Autolus Therapeutics price target lowered to $11 from $13 at Truist
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
12/20/21 H.C. Wainwright
Autolus Therapeutics price target lowered to $11 from $13 at H.C. Wainwright
HALO Halozyme
$39.63 /

+0.25 (+0.63%)

08/10/22 Benchmark
Halozyme recent weakness a buying opportunity, says Benchmark
05/23/22 SVB Securities
Halozyme initiated with an Outperform at SVB Leerink
04/14/22 Truist
Antares Pharma downgraded to Hold from Buy at Truist
04/14/22 Raymond James
Antares Pharma downgraded to Market Perform from Strong Buy at Raymond James
IMVT Immunovant
$5.06 /

+0.145 (+2.95%)

03/30/22 Chardan
Immunovant price target lowered to $14 from $20 at Chardan
01/05/22 Chardan
Immunovant price target lowered to $20 from $22 at Chardan
12/31/21 Wells Fargo
Immunovant shares to remain range-bound in 2022, says Wells Fargo
12/08/21 Wells Fargo
Immunovant initiated with an Equal Weight at Wells Fargo
JNCE Jounce Therapeutics
$3.49 /

-0.06 (-1.69%)

08/30/22 Piper Sandler
Jounce Therapeutics price target lowered to $6 from $9 at Piper Sandler
08/05/22 H.C. Wainwright
Jounce Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
05/23/22 Piper Sandler
Jounce Therapeutics price target lowered to $9 from $17 at Piper Sandler
05/12/22 Roth Capital
Jounce Therapeutics recent pullback overdone, says Roth Capital
IDYA Ideaya Biosciences
$9.31 /

+0.01 (+0.11%)

08/16/22 Baird
Ideaya Biosciences price target lowered to $18 from $26 at Baird
08/16/22 Oppenheimer
Ideaya Biosciences price target lowered to $20 from $25 at Oppenheimer
08/15/22 Stifel
Ideaya Biosciences downgraded to Hold at Stifel after GSK waives IDE397 opt-in
08/15/22 Stifel
Ideaya Biosciences downgraded to Hold from Buy at Stifel
SYK Stryker
$220.34 /

+9.14 (+4.33%)

09/06/22 BTIG
Stryker price target lowered to $238 from $244 at BTIG
07/28/22 Edward Jones
Stryker upgraded to Buy at Edward Jones following pullback
07/28/22 Edward Jones
Stryker upgraded to Buy from Hold at Edward Jones
07/27/22 Wells Fargo
Stryker price target lowered to $237 from $286 at Wells Fargo
NPCE NeuroPace
$4.50 /

-0.275 (-5.77%)

04/05/22 Wolfe Research
NeuroPace initiated with an Outperform at Wolfe Research
01/19/22 Wells Fargo
Wells Fargo downgrades NeuroPace to Equal Weight, lowers price target to $11
01/19/22 Wells Fargo
NeuroPace downgraded to Equal Weight from Overweight at Wells Fargo
01/07/22 Morgan Stanley
NeuroPace cut to Underweight at Morgan Stanley on cloudy near-term outlook
IONS Ionis Pharmaceuticals
$44.28 /

+0.9 (+2.07%)

08/10/22 Citi
Ionis Pharmaceuticals price target raised to $28 from $26 at Citi
07/26/22 Piper Sandler
Ionis Pharmaceuticals price target raised to $58 from $55 at Piper Sandler
07/20/22 Piper Sandler
Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
07/18/22 Oppenheimer
Ionis Pharmaceuticals assumed with an Outperform at Oppenheimer
HRMY Harmony Biosciences
$47.66 /

+1.675 (+3.64%)

09/01/22 Mizuho
Harmony Biosciences recent weakness a buying opportunity, says Mizuho
08/18/22 Mizuho
Harmony Biosciences Orange Book update 'incremental negative,' says Mizuho
08/03/22 Jefferies
Jefferies downgrades Harmony Biosciences to Hold, sees limited near-term upside
08/03/22 Oppenheimer
Harmony Biosciences price target raised to $67 from $62 at Oppenheimer
WAT Waters
$308.63 /

+6.55 (+2.17%)

SYK Stryker
$220.34 /

+9.14 (+4.33%)

SWAV ShockWave Medical
$292.67 /

+4.85 (+1.69%)

SUPN Supernus
$34.53 /

+0.34 (+0.99%)

RGLS Regulus
$1.61 /

+0.04 (+2.55%)

PGEN Precigen
$2.46 /

+0.145 (+6.28%)

PEN Penumbra
$197.58 /

+11.9 (+6.41%)

ORIC Oric Pharmaceuticals
$3.56 /

+0.12 (+3.49%)

NUVA NuVasive
$46.21 /

+0.89 (+1.96%)

NRIX Nurix Therapeutics
$15.99 /

-0.13 (-0.81%)

NPCE NeuroPace
$4.50 /

-0.275 (-5.77%)

LEGN Legend Biotech
$43.61 /

-0.25 (-0.57%)

KYMR Kymera Therapeutics
$28.76 /

+0.27 (+0.95%)

JNCE Jounce Therapeutics
$3.49 /

-0.06 (-1.69%)

IONS Ionis Pharmaceuticals
$44.28 /

+0.9 (+2.07%)

INSP Inspire Medical
$197.41 /

+8.2 (+4.33%)

INGN Inogen
$27.44 /

-0.75 (-2.66%)

IMVT Immunovant
$5.06 /

+0.145 (+2.95%)

IDYA Ideaya Biosciences
$9.31 /

+0.01 (+0.11%)

HRMY Harmony Biosciences
$47.66 /

+1.675 (+3.64%)

HOLX Hologic
$68.88 /

+1.17 (+1.73%)

HALO Halozyme
$39.63 /

+0.25 (+0.63%)

GILD Gilead
$65.11 /

+0.325 (+0.50%)

FATE Fate Therapeutics
$28.25 /

+0.935 (+3.42%)

DGX Quest Diagnostics
$130.17 /

+2.86 (+2.25%)

BNFT Benefitfocus
$6.92 /

-0.13 (-1.84%)

AVEO Aveo Pharmaceuticals
$8.59 /

+0.28 (+3.37%)

AUTL Autolus Therapeutics
$3.12 /

+0.19 (+6.48%)

ABBV AbbVie
$140.52 /

+1.48 (+1.06%)

  • 12
    Aug
  • 27
    Jul
  • 16
    Dec
SYK Stryker
$220.34 /

+9.14 (+4.33%)

SWAV ShockWave Medical
$292.67 /

+4.85 (+1.69%)

GILD Gilead
$65.11 /

+0.325 (+0.50%)

ABBV AbbVie
$140.52 /

+1.48 (+1.06%)

SYK Stryker
$220.34 /

+9.14 (+4.33%)

SWAV ShockWave Medical
$292.67 /

+4.85 (+1.69%)

SUPN Supernus
$34.53 /

+0.34 (+0.99%)

PEN Penumbra
$197.58 /

+11.9 (+6.41%)

ORIC Oric Pharmaceuticals
$3.56 /

+0.12 (+3.49%)

NUVA NuVasive
$46.21 /

+0.89 (+1.96%)

NRIX Nurix Therapeutics
$15.99 /

-0.13 (-0.81%)

LEGN Legend Biotech
$43.61 /

-0.25 (-0.57%)

KYMR Kymera Therapeutics
$28.76 /

+0.27 (+0.95%)

JNCE Jounce Therapeutics
$3.49 /

-0.06 (-1.69%)

IDYA Ideaya Biosciences
$9.31 /

+0.01 (+0.11%)

HRMY Harmony Biosciences
$47.66 /

+1.675 (+3.64%)

HOLX Hologic
$68.88 /

+1.17 (+1.73%)

HALO Halozyme
$39.63 /

+0.25 (+0.63%)

GILD Gilead
$65.11 /

+0.325 (+0.50%)

FATE Fate Therapeutics
$28.25 /

+0.935 (+3.42%)

DGX Quest Diagnostics
$130.17 /

+2.86 (+2.25%)

AVEO Aveo Pharmaceuticals
$8.59 /

+0.28 (+3.37%)

ABBV AbbVie
$140.52 /

+1.48 (+1.06%)

WAT Waters
$308.63 /

+6.55 (+2.17%)

SYK Stryker
$220.34 /

+9.14 (+4.33%)

GILD Gilead
$65.11 /

+0.325 (+0.50%)

ABBV AbbVie
$140.52 /

+1.48 (+1.06%)

Conference/Events
Wells Fargo to hold a conference » 04:55
09/08/22
09/08
04:55
09/08/22
04:55
ABBV

AbbVie

$139.04 /

+1.4 (+1.02%)

, AVEO

Aveo Pharmaceuticals

$8.31 /

+0.33 (+4.14%)

, BNFT

Benefitfocus

$7.04 /

+0.33 (+4.92%)

, DGX

Quest Diagnostics

$127.38 /

+2.27 (+1.81%)

, FATE

Fate Therapeutics

$27.31 /

+2.02 (+7.99%)

, INSP

Inspire Medical

$188.93 /

+5.92 (+3.23%)

, LEGN

Legend Biotech

$43.86 /

-0.17 (-0.39%)

, GILD

Gilead

$64.79 /

+1.355 (+2.14%)

, HOLX

Hologic

$67.71 /

+0.33 (+0.49%)

, INGN

Inogen

$28.19 /

+0.6 (+2.17%)

, KYMR

Kymera Therapeutics

$28.47 /

+2.545 (+9.82%)

, NOTV

Inotiv

$20.88 /

+0.24 (+1.16%)

, PEN

Penumbra

$186.16 /

+21.935 (+13.36%)

, RGLS

Regulus

$1.57 /

-0.01 (-0.63%)

, SWAV

ShockWave Medical

$286.96 /

+12.165 (+4.43%)

, WAT

Waters

$302.21 /

+4.705 (+1.58%)

, SUPN

Supernus

$34.19 /

+0.15 (+0.44%)

, ORIC

Oric Pharmaceuticals

$3.46 /

-0.09 (-2.54%)

, PGEN

Precigen

$2.31 /

+0.025 (+1.09%)

, NRIX

Nurix Therapeutics

$16.12 /

+0.83 (+5.43%)

, NUVA

NuVasive

$45.32 /

+2.34 (+5.44%)

, AUTL

Autolus Therapeutics

$2.94 /

-0.15 (-4.85%)

, HALO

Halozyme

$39.39 /

+0.845 (+2.19%)

, IMVT

Immunovant

$4.92 /

+0.03 (+0.61%)

, JNCE

Jounce Therapeutics

$3.55 /

+0.05 (+1.43%)

, IDYA

Ideaya Biosciences

$9.29 /

+0.05 (+0.54%)

, SYK

Stryker

$211.20 /

+8.39 (+4.14%)

, NPCE

NeuroPace

$4.73 /

+0.01 (+0.21%)

, IONS

Ionis Pharmaceuticals

$43.43 /

+1.75 (+4.20%)

, HRMY

Harmony Biosciences

$46.06 /

+1.7 (+3.83%)

2022 Wells Fargo…

2022 Wells Fargo Healthcare Conference to be held in Everett, MA on September 7-9.

ShowHide Related Items >><<
SYK Stryker
$211.20 /

+8.39 (+4.14%)

SWAV ShockWave Medical
$286.96 /

+12.165 (+4.43%)

SUPN Supernus
$34.19 /

+0.15 (+0.44%)

RGLS Regulus
$1.57 /

-0.01 (-0.63%)

PGEN Precigen
$2.31 /

+0.025 (+1.09%)

ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

NUVA NuVasive
$45.32 /

+2.34 (+5.44%)

NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

NPCE NeuroPace
$4.73 /

+0.01 (+0.21%)

NOTV Inotiv
$20.88 /

+0.24 (+1.16%)

LEGN Legend Biotech
$43.86 /

-0.17 (-0.39%)

KYMR Kymera Therapeutics
$28.47 /

+2.545 (+9.82%)

JNCE Jounce Therapeutics
$3.55 /

+0.05 (+1.43%)

IONS Ionis Pharmaceuticals
$43.43 /

+1.75 (+4.20%)

INSP Inspire Medical
$188.93 /

+5.92 (+3.23%)

IMVT Immunovant
$4.92 /

+0.03 (+0.61%)

IDYA Ideaya Biosciences
$9.29 /

+0.05 (+0.54%)

HRMY Harmony Biosciences
$46.06 /

+1.7 (+3.83%)

HOLX Hologic
$67.71 /

+0.33 (+0.49%)

HALO Halozyme
$39.39 /

+0.845 (+2.19%)

GILD Gilead
$64.79 /

+1.355 (+2.14%)

FATE Fate Therapeutics
$27.31 /

+2.02 (+7.99%)

DGX Quest Diagnostics
$127.38 /

+2.27 (+1.81%)

BNFT Benefitfocus
$7.04 /

+0.33 (+4.92%)

AVEO Aveo Pharmaceuticals
$8.31 /

+0.33 (+4.14%)

AUTL Autolus Therapeutics
$2.94 /

-0.15 (-4.85%)

ABBV AbbVie
$139.04 /

+1.4 (+1.02%)

ABBV AbbVie
$139.04 /

+1.4 (+1.02%)

08/30/22 Piper Sandler
I-Mab price target lowered to $30 from $35 at Piper Sandler
08/24/22 Argus
AbbVie price target lowered to $155 from $165 at Argus
08/01/22 JPMorgan
AbbVie selloff Friday a buying opportunity, says JPMorgan
08/01/22 Barclays
AbbVie price target lowered to $160 from $174 at Barclays
AVEO Aveo Pharmaceuticals
$8.31 /

+0.33 (+4.14%)

03/14/22 JonesTrading
Aveo Pharmaceuticals initiated with a Buy at JonesTrading
BNFT Benefitfocus
$7.04 /

+0.33 (+4.92%)

09/06/22 Piper Sandler
Benefitfocus price target lowered to $6 from $9 at Piper Sandler
06/22/22 Piper Sandler
Benefitfocus downgraded to Neutral from Overweight at Piper Sandler
DGX Quest Diagnostics
$127.38 /

+2.27 (+1.81%)

08/22/22 Morgan Stanley
Quest Diagnostics assumed with an Equal Weight at Morgan Stanley
07/22/22 Mizuho
Quest Diagnostics price target lowered to $160 from $185 at Mizuho
07/22/22 Credit Suisse
Quest Diagnostics price target lowered to $143 from $158 at Credit Suisse
04/24/22 UBS
Quest Diagnostics price target raised to $150 from $139 at UBS
FATE Fate Therapeutics
$27.31 /

+2.02 (+7.99%)

08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
08/04/22 Oppenheimer
Fate Therapeutics price target lowered to $90 from $135 at Oppenheimer
07/28/22 Needham
Fate Therapeutics initiated with a Hold at Needham
07/11/22 BMO Capital
Fate Therapeutics upgraded to Outperform from Market Perform at BMO Capital
INSP Inspire Medical
$188.93 /

+5.92 (+3.23%)

08/03/22 Truist
Inspire Medical price target raised to $280 from $250 at Truist
08/03/22 Piper Sandler
Inspire Medical price target lowered to $285 from $310 at Piper Sandler
07/05/22 Piper Sandler
Piper says Inspire appears to have received FDA approval for expanded labeling
06/10/22 Truist
Inspire Medical price target lowered to $250 from $296 at Truist
LEGN Legend Biotech
$43.86 /

-0.17 (-0.39%)

07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
06/16/22 BMO Capital
Legend Biotech initiated with an Outperform at BMO Capital
05/31/22 Morgan Stanley
Legend Biotech named Catalyst Driven Idea by Morgan Stanley
03/15/22 Barclays
Legend Biotech initiated with an Overweight at Barclays
GILD Gilead
$64.79 /

+1.355 (+2.14%)

09/02/22 Argus
Gilead pullback provides favorable entry point, says Argus
08/15/22 Piper Sandler
Gilead's Trodelvy shows OS benefit in HR+/HER- BC, says Piper Sandler
08/15/22 Piper Sandler
Gilead price target raised to $74 from $71 at Piper Sandler
08/08/22 Truist
Gilead price target lowered to $71 from $75 at Truist
HOLX Hologic
$67.71 /

+0.33 (+0.49%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
INGN Inogen
$28.19 /

+0.6 (+2.17%)

05/09/22 Stifel
Inogen price target lowered to $30 from $40 at Stifel
12/09/21 Needham
Inogen upgraded to Buy from Hold at Needham
12/09/21 Needham
Inogen upgraded to Buy from Hold at Needham
11/02/21
Fly Intel: Top five analyst upgrades
KYMR Kymera Therapeutics
$28.47 /

+2.545 (+9.82%)

08/31/22 JPMorgan
Kymera selloff a 'misplaced knee-jerk reaction,' says JPMorgan
08/15/22 Jefferies
Kymera Therapeutics initiated with a Buy at Jefferies
08/03/22 Goldman Sachs
Kymera Therapeutics initiated with a Buy at Goldman Sachs
07/20/22 SVB Securities
Kymera Therapeutics initiated with a Market Perform at SVB Securities
NOTV Inotiv
$20.88 /

+0.24 (+1.16%)

08/11/22 Lake Street
Inotiv price target raised to $60 from $50 at Lake Street
06/14/22 Lake Street
Inotiv price target lowered to $50 from $75 at Lake Street
02/11/22 Lake Street
Inotiv price target raised to $75 from $60 at Lake Street
02/02/22 Craig-Hallum
Inotiv price target raised to $64 from $57 at Craig-Hallum
PEN Penumbra
$186.16 /

+21.935 (+13.36%)

08/05/22 Canaccord
Penumbra price target lowered to $189 from $244 at Canaccord
07/21/22 Deutsche Bank
Penumbra price target lowered to $163 from $250 at Deutsche Bank
07/18/22 BTIG
Penumbra price target lowered to $213 from $272 at BTIG
07/18/22 RBC Capital
Penumbra initiated with an Outperform at RBC Capital
RGLS Regulus
$1.57 /

-0.01 (-0.63%)

SWAV ShockWave Medical
$286.96 /

+12.165 (+4.43%)

09/06/22 Oppenheimer
Oppenheimer downgrades ShockWave Medical to Underperform with $165 price target
09/06/22 Oppenheimer
ShockWave Medical downgraded to Underperform from Perform at Oppenheimer
08/29/22 Piper Sandler
ShockWave Medical price target raised to $338 from $278 at Piper Sandler
08/09/22 Canaccord
ShockWave Medical price target raised to $256 from $232 at Canaccord
WAT Waters
$302.21 /

+4.705 (+1.58%)

08/24/22 Credit Suisse
Waters initiated with a Neutral at Credit Suisse
08/03/22 Baird
Waters price target raised to $348 from $340 at Baird
07/20/22 UBS
Waters initiated with a Neutral at UBS
07/05/22 Evercore ISI
Waters added to 'Tactical Outperform' list at Evercore ISI
SUPN Supernus
$34.19 /

+0.15 (+0.44%)

08/31/22 Piper Sandler
Supernus price target raised to $38 from $33 at Piper Sandler
12/01/21 Jefferies
Supernus resumed with a Buy at Jefferies
10/12/21 JMP Securities
Adamas Pharmaceuticals cut to Market Perform from Outperform at JMP Securities
10/12/21 H.C. Wainwright
Adamas Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

07/15/22 Oppenheimer
Oric Pharmaceuticals assumed with a Perform at Oppenheimer
04/04/22 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/22 H.C. Wainwright
Oric Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
03/22/22 Guggenheim
Oric downgraded to Neutral at Guggenheim after ORIC-101 discontinuation
PGEN Precigen
$2.31 /

+0.025 (+1.09%)

08/09/22 H.C. Wainwright
Precigen price target lowered to $6 from $10 at H.C. Wainwright
07/05/22 Stifel
Precigen subsidiary sale relieves convertible debt overhang, says Stifel
NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

07/11/22 H.C. Wainwright
Nurix Therapeutics price target lowered to $54 from $60 at H.C. Wainwright
07/08/22 Stifel
Nurix Therapeutics price target lowered to $37 from $44 at Stifel
07/08/22 JPMorgan
Nurix Therapeutics price target lowered to $37 from $46 at JPMorgan
07/08/22 Baird
Nurix Therapeutics price target lowered to $32 from $41 at Baird
NUVA NuVasive
$45.32 /

+2.34 (+5.44%)

08/23/22 Piper Sandler
NuVasive selloff on bus tour comments an opportunity, says Piper Sandler
08/04/22 Canaccord
NuVasive price target raised to $55 from $50 at Canaccord
08/04/22 Piper Sandler
NuVasive price target lowered to $60 from $80 at Piper Sandler
06/28/22 Stifel
Stifel cuts Orthofix target, says momentum 'faded' during Q2
AUTL Autolus Therapeutics
$2.94 /

-0.15 (-4.85%)

06/14/22 Truist
Autolus Therapeutics price target lowered to $11 from $13 at Truist
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
12/20/21 H.C. Wainwright
Autolus Therapeutics price target lowered to $11 from $13 at H.C. Wainwright
HALO Halozyme
$39.39 /

+0.845 (+2.19%)

08/10/22 Benchmark
Halozyme recent weakness a buying opportunity, says Benchmark
05/23/22 SVB Securities
Halozyme initiated with an Outperform at SVB Leerink
04/14/22 Truist
Antares Pharma downgraded to Hold from Buy at Truist
04/14/22 Raymond James
Antares Pharma downgraded to Market Perform from Strong Buy at Raymond James
IMVT Immunovant
$4.92 /

+0.03 (+0.61%)

03/30/22 Chardan
Immunovant price target lowered to $14 from $20 at Chardan
01/05/22 Chardan
Immunovant price target lowered to $20 from $22 at Chardan
12/31/21 Wells Fargo
Immunovant shares to remain range-bound in 2022, says Wells Fargo
12/08/21 Wells Fargo
Immunovant initiated with an Equal Weight at Wells Fargo
JNCE Jounce Therapeutics
$3.55 /

+0.05 (+1.43%)

08/30/22 Piper Sandler
Jounce Therapeutics price target lowered to $6 from $9 at Piper Sandler
08/05/22 H.C. Wainwright
Jounce Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
05/23/22 Piper Sandler
Jounce Therapeutics price target lowered to $9 from $17 at Piper Sandler
05/12/22 Roth Capital
Jounce Therapeutics recent pullback overdone, says Roth Capital
IDYA Ideaya Biosciences
$9.29 /

+0.05 (+0.54%)

08/16/22 Baird
Ideaya Biosciences price target lowered to $18 from $26 at Baird
08/16/22 Oppenheimer
Ideaya Biosciences price target lowered to $20 from $25 at Oppenheimer
08/15/22 Stifel
Ideaya Biosciences downgraded to Hold at Stifel after GSK waives IDE397 opt-in
08/15/22 Stifel
Ideaya Biosciences downgraded to Hold from Buy at Stifel
SYK Stryker
$211.20 /

+8.39 (+4.14%)

09/06/22 BTIG
Stryker price target lowered to $238 from $244 at BTIG
07/28/22 Edward Jones
Stryker upgraded to Buy at Edward Jones following pullback
07/28/22 Edward Jones
Stryker upgraded to Buy from Hold at Edward Jones
07/27/22 Wells Fargo
Stryker price target lowered to $237 from $286 at Wells Fargo
NPCE NeuroPace
$4.73 /

+0.01 (+0.21%)

04/05/22 Wolfe Research
NeuroPace initiated with an Outperform at Wolfe Research
01/19/22 Wells Fargo
Wells Fargo downgrades NeuroPace to Equal Weight, lowers price target to $11
01/19/22 Wells Fargo
NeuroPace downgraded to Equal Weight from Overweight at Wells Fargo
01/07/22 Morgan Stanley
NeuroPace cut to Underweight at Morgan Stanley on cloudy near-term outlook
IONS Ionis Pharmaceuticals
$43.43 /

+1.75 (+4.20%)

08/10/22 Citi
Ionis Pharmaceuticals price target raised to $28 from $26 at Citi
07/26/22 Piper Sandler
Ionis Pharmaceuticals price target raised to $58 from $55 at Piper Sandler
07/20/22 Piper Sandler
Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
07/18/22 Oppenheimer
Ionis Pharmaceuticals assumed with an Outperform at Oppenheimer
HRMY Harmony Biosciences
$46.06 /

+1.7 (+3.83%)

09/01/22 Mizuho
Harmony Biosciences recent weakness a buying opportunity, says Mizuho
08/18/22 Mizuho
Harmony Biosciences Orange Book update 'incremental negative,' says Mizuho
08/03/22 Jefferies
Jefferies downgrades Harmony Biosciences to Hold, sees limited near-term upside
08/03/22 Oppenheimer
Harmony Biosciences price target raised to $67 from $62 at Oppenheimer
WAT Waters
$302.21 /

+4.705 (+1.58%)

SYK Stryker
$211.20 /

+8.39 (+4.14%)

SWAV ShockWave Medical
$286.96 /

+12.165 (+4.43%)

SUPN Supernus
$34.19 /

+0.15 (+0.44%)

RGLS Regulus
$1.57 /

-0.01 (-0.63%)

PGEN Precigen
$2.31 /

+0.025 (+1.09%)

PEN Penumbra
$186.16 /

+21.935 (+13.36%)

ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

NUVA NuVasive
$45.32 /

+2.34 (+5.44%)

NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

NPCE NeuroPace
$4.73 /

+0.01 (+0.21%)

LEGN Legend Biotech
$43.86 /

-0.17 (-0.39%)

KYMR Kymera Therapeutics
$28.47 /

+2.545 (+9.82%)

JNCE Jounce Therapeutics
$3.55 /

+0.05 (+1.43%)

IONS Ionis Pharmaceuticals
$43.43 /

+1.75 (+4.20%)

INSP Inspire Medical
$188.93 /

+5.92 (+3.23%)

INGN Inogen
$28.19 /

+0.6 (+2.17%)

IMVT Immunovant
$4.92 /

+0.03 (+0.61%)

IDYA Ideaya Biosciences
$9.29 /

+0.05 (+0.54%)

HRMY Harmony Biosciences
$46.06 /

+1.7 (+3.83%)

HOLX Hologic
$67.71 /

+0.33 (+0.49%)

HALO Halozyme
$39.39 /

+0.845 (+2.19%)

GILD Gilead
$64.79 /

+1.355 (+2.14%)

FATE Fate Therapeutics
$27.31 /

+2.02 (+7.99%)

DGX Quest Diagnostics
$127.38 /

+2.27 (+1.81%)

BNFT Benefitfocus
$7.04 /

+0.33 (+4.92%)

AVEO Aveo Pharmaceuticals
$8.31 /

+0.33 (+4.14%)

AUTL Autolus Therapeutics
$2.94 /

-0.15 (-4.85%)

ABBV AbbVie
$139.04 /

+1.4 (+1.02%)

  • 12
    Aug
  • 27
    Jul
  • 16
    Dec
SYK Stryker
$211.20 /

+8.39 (+4.14%)

GILD Gilead
$64.79 /

+1.355 (+2.14%)

ABBV AbbVie
$139.04 /

+1.4 (+1.02%)

SYK Stryker
$211.20 /

+8.39 (+4.14%)

SWAV ShockWave Medical
$286.96 /

+12.165 (+4.43%)

SUPN Supernus
$34.19 /

+0.15 (+0.44%)

PEN Penumbra
$186.16 /

+21.935 (+13.36%)

ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

NUVA NuVasive
$45.32 /

+2.34 (+5.44%)

NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

LEGN Legend Biotech
$43.86 /

-0.17 (-0.39%)

KYMR Kymera Therapeutics
$28.47 /

+2.545 (+9.82%)

JNCE Jounce Therapeutics
$3.55 /

+0.05 (+1.43%)

IDYA Ideaya Biosciences
$9.29 /

+0.05 (+0.54%)

HRMY Harmony Biosciences
$46.06 /

+1.7 (+3.83%)

HOLX Hologic
$67.71 /

+0.33 (+0.49%)

HALO Halozyme
$39.39 /

+0.845 (+2.19%)

GILD Gilead
$64.79 /

+1.355 (+2.14%)

FATE Fate Therapeutics
$27.31 /

+2.02 (+7.99%)

DGX Quest Diagnostics
$127.38 /

+2.27 (+1.81%)

AVEO Aveo Pharmaceuticals
$8.31 /

+0.33 (+4.14%)

ABBV AbbVie
$139.04 /

+1.4 (+1.02%)

WAT Waters
$302.21 /

+4.705 (+1.58%)

SYK Stryker
$211.20 /

+8.39 (+4.14%)

GILD Gilead
$64.79 /

+1.355 (+2.14%)

ABBV AbbVie
$139.04 /

+1.4 (+1.02%)

Conference/Events
Wells Fargo to hold a conference » 16:08
09/07/22
09/07
16:08
09/07/22
16:08
ABBV

AbbVie

$138.72 /

+1.08 (+0.78%)

, AVEO

Aveo Pharmaceuticals

$8.35 /

+0.37 (+4.64%)

, BNFT

Benefitfocus

$7.02 /

+0.31 (+4.62%)

, DGX

Quest Diagnostics

$127.43 /

+2.325 (+1.86%)

, FATE

Fate Therapeutics

$27.32 /

+2.03 (+8.03%)

, INSP

Inspire Medical

$188.51 /

+5.5 (+3.01%)

, LEGN

Legend Biotech

$43.82 /

-0.21 (-0.48%)

, GILD

Gilead

$64.88 /

+1.45 (+2.29%)

, HOLX

Hologic

$67.72 /

+0.34 (+0.50%)

, INGN

Inogen

$28.45 /

+0.86 (+3.12%)

, KYMR

Kymera Therapeutics

$28.48 /

+2.555 (+9.86%)

, NOTV

Inotiv

$21.03 /

+0.39 (+1.89%)

, PEN

Penumbra

$184.98 /

+20.76 (+12.64%)

, RGLS

Regulus

$1.54 /

-0.04 (-2.53%)

, SWAV

ShockWave Medical

$287.16 /

+12.37 (+4.50%)

, WAT

Waters

$302.39 /

+4.89 (+1.64%)

, SUPN

Supernus

$34.11 /

+0.07 (+0.21%)

, ORIC

Oric Pharmaceuticals

$3.46 /

-0.09 (-2.54%)

, PGEN

Precigen

$2.31 /

+0.02 (+0.88%)

, NRIX

Nurix Therapeutics

$16.12 /

+0.83 (+5.43%)

, NUVA

NuVasive

$45.25 /

+2.27 (+5.28%)

, AUTL

Autolus Therapeutics

$2.93 /

-0.16 (-5.18%)

, HALO

Halozyme

$39.40 /

+0.855 (+2.22%)

, IMVT

Immunovant

$4.95 /

+0.06 (+1.23%)

, JNCE

Jounce Therapeutics

$3.61 /

+0.11 (+3.14%)

, IDYA

Ideaya Biosciences

$9.25 /

+0.01 (+0.11%)

, SYK

Stryker

$210.95 /

+8.14 (+4.01%)

, NPCE

NeuroPace

$4.73 /

+0.01 (+0.21%)

, IONS

Ionis Pharmaceuticals

$43.27 /

+1.585 (+3.80%)

, HRMY

Harmony Biosciences

$45.98 /

+1.62 (+3.65%)

2022 Wells Fargo…

2022 Wells Fargo Healthcare Conference to be held in Everett, MA on September 7-9.

ShowHide Related Items >><<
SYK Stryker
$210.95 /

+8.14 (+4.01%)

SWAV ShockWave Medical
$287.16 /

+12.37 (+4.50%)

SUPN Supernus
$34.11 /

+0.07 (+0.21%)

RGLS Regulus
$1.54 /

-0.04 (-2.53%)

PGEN Precigen
$2.31 /

+0.02 (+0.88%)

ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

NUVA NuVasive
$45.25 /

+2.27 (+5.28%)

NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

NPCE NeuroPace
$4.73 /

+0.01 (+0.21%)

NOTV Inotiv
$21.03 /

+0.39 (+1.89%)

LEGN Legend Biotech
$43.82 /

-0.21 (-0.48%)

KYMR Kymera Therapeutics
$28.48 /

+2.555 (+9.86%)

JNCE Jounce Therapeutics
$3.61 /

+0.11 (+3.14%)

IONS Ionis Pharmaceuticals
$43.27 /

+1.585 (+3.80%)

INSP Inspire Medical
$188.51 /

+5.5 (+3.01%)

IMVT Immunovant
$4.95 /

+0.06 (+1.23%)

IDYA Ideaya Biosciences
$9.25 /

+0.01 (+0.11%)

HRMY Harmony Biosciences
$45.98 /

+1.62 (+3.65%)

HOLX Hologic
$67.72 /

+0.34 (+0.50%)

HALO Halozyme
$39.40 /

+0.855 (+2.22%)

GILD Gilead
$64.88 /

+1.45 (+2.29%)

FATE Fate Therapeutics
$27.32 /

+2.03 (+8.03%)

DGX Quest Diagnostics
$127.43 /

+2.325 (+1.86%)

BNFT Benefitfocus
$7.02 /

+0.31 (+4.62%)

AVEO Aveo Pharmaceuticals
$8.35 /

+0.37 (+4.64%)

AUTL Autolus Therapeutics
$2.93 /

-0.16 (-5.18%)

ABBV AbbVie
$138.72 /

+1.08 (+0.78%)

ABBV AbbVie
$138.72 /

+1.08 (+0.78%)

08/30/22 Piper Sandler
I-Mab price target lowered to $30 from $35 at Piper Sandler
08/24/22 Argus
AbbVie price target lowered to $155 from $165 at Argus
08/01/22 JPMorgan
AbbVie selloff Friday a buying opportunity, says JPMorgan
08/01/22 Barclays
AbbVie price target lowered to $160 from $174 at Barclays
AVEO Aveo Pharmaceuticals
$8.35 /

+0.37 (+4.64%)

03/14/22 JonesTrading
Aveo Pharmaceuticals initiated with a Buy at JonesTrading
BNFT Benefitfocus
$7.02 /

+0.31 (+4.62%)

09/06/22 Piper Sandler
Benefitfocus price target lowered to $6 from $9 at Piper Sandler
06/22/22 Piper Sandler
Benefitfocus downgraded to Neutral from Overweight at Piper Sandler
DGX Quest Diagnostics
$127.43 /

+2.325 (+1.86%)

08/22/22 Morgan Stanley
Quest Diagnostics assumed with an Equal Weight at Morgan Stanley
07/22/22 Mizuho
Quest Diagnostics price target lowered to $160 from $185 at Mizuho
07/22/22 Credit Suisse
Quest Diagnostics price target lowered to $143 from $158 at Credit Suisse
04/24/22 UBS
Quest Diagnostics price target raised to $150 from $139 at UBS
FATE Fate Therapeutics
$27.32 /

+2.03 (+8.03%)

08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
08/04/22 Oppenheimer
Fate Therapeutics price target lowered to $90 from $135 at Oppenheimer
07/28/22 Needham
Fate Therapeutics initiated with a Hold at Needham
07/11/22 BMO Capital
Fate Therapeutics upgraded to Outperform from Market Perform at BMO Capital
INSP Inspire Medical
$188.51 /

+5.5 (+3.01%)

08/03/22 Truist
Inspire Medical price target raised to $280 from $250 at Truist
08/03/22 Piper Sandler
Inspire Medical price target lowered to $285 from $310 at Piper Sandler
07/05/22 Piper Sandler
Piper says Inspire appears to have received FDA approval for expanded labeling
06/10/22 Truist
Inspire Medical price target lowered to $250 from $296 at Truist
LEGN Legend Biotech
$43.82 /

-0.21 (-0.48%)

07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
06/16/22 BMO Capital
Legend Biotech initiated with an Outperform at BMO Capital
05/31/22 Morgan Stanley
Legend Biotech named Catalyst Driven Idea by Morgan Stanley
03/15/22 Barclays
Legend Biotech initiated with an Overweight at Barclays
GILD Gilead
$64.88 /

+1.45 (+2.29%)

09/02/22 Argus
Gilead pullback provides favorable entry point, says Argus
08/15/22 Piper Sandler
Gilead's Trodelvy shows OS benefit in HR+/HER- BC, says Piper Sandler
08/15/22 Piper Sandler
Gilead price target raised to $74 from $71 at Piper Sandler
08/08/22 Truist
Gilead price target lowered to $71 from $75 at Truist
HOLX Hologic
$67.72 /

+0.34 (+0.50%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
INGN Inogen
$28.45 /

+0.86 (+3.12%)

05/09/22 Stifel
Inogen price target lowered to $30 from $40 at Stifel
12/09/21 Needham
Inogen upgraded to Buy from Hold at Needham
12/09/21 Needham
Inogen upgraded to Buy from Hold at Needham
11/02/21
Fly Intel: Top five analyst upgrades
KYMR Kymera Therapeutics
$28.48 /

+2.555 (+9.86%)

08/31/22 JPMorgan
Kymera selloff a 'misplaced knee-jerk reaction,' says JPMorgan
08/15/22 Jefferies
Kymera Therapeutics initiated with a Buy at Jefferies
08/03/22 Goldman Sachs
Kymera Therapeutics initiated with a Buy at Goldman Sachs
07/20/22 SVB Securities
Kymera Therapeutics initiated with a Market Perform at SVB Securities
NOTV Inotiv
$21.03 /

+0.39 (+1.89%)

08/11/22 Lake Street
Inotiv price target raised to $60 from $50 at Lake Street
06/14/22 Lake Street
Inotiv price target lowered to $50 from $75 at Lake Street
02/11/22 Lake Street
Inotiv price target raised to $75 from $60 at Lake Street
02/02/22 Craig-Hallum
Inotiv price target raised to $64 from $57 at Craig-Hallum
PEN Penumbra
$184.98 /

+20.76 (+12.64%)

08/05/22 Canaccord
Penumbra price target lowered to $189 from $244 at Canaccord
07/21/22 Deutsche Bank
Penumbra price target lowered to $163 from $250 at Deutsche Bank
07/18/22 BTIG
Penumbra price target lowered to $213 from $272 at BTIG
07/18/22 RBC Capital
Penumbra initiated with an Outperform at RBC Capital
RGLS Regulus
$1.54 /

-0.04 (-2.53%)

SWAV ShockWave Medical
$287.16 /

+12.37 (+4.50%)

09/06/22 Oppenheimer
Oppenheimer downgrades ShockWave Medical to Underperform with $165 price target
09/06/22 Oppenheimer
ShockWave Medical downgraded to Underperform from Perform at Oppenheimer
08/29/22 Piper Sandler
ShockWave Medical price target raised to $338 from $278 at Piper Sandler
08/09/22 Canaccord
ShockWave Medical price target raised to $256 from $232 at Canaccord
WAT Waters
$302.39 /

+4.89 (+1.64%)

08/24/22 Credit Suisse
Waters initiated with a Neutral at Credit Suisse
08/03/22 Baird
Waters price target raised to $348 from $340 at Baird
07/20/22 UBS
Waters initiated with a Neutral at UBS
07/05/22 Evercore ISI
Waters added to 'Tactical Outperform' list at Evercore ISI
SUPN Supernus
$34.11 /

+0.07 (+0.21%)

08/31/22 Piper Sandler
Supernus price target raised to $38 from $33 at Piper Sandler
12/01/21 Jefferies
Supernus resumed with a Buy at Jefferies
10/12/21 JMP Securities
Adamas Pharmaceuticals cut to Market Perform from Outperform at JMP Securities
10/12/21 H.C. Wainwright
Adamas Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

07/15/22 Oppenheimer
Oric Pharmaceuticals assumed with a Perform at Oppenheimer
04/04/22 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/22 H.C. Wainwright
Oric Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
03/22/22 Guggenheim
Oric downgraded to Neutral at Guggenheim after ORIC-101 discontinuation
PGEN Precigen
$2.31 /

+0.02 (+0.88%)

08/09/22 H.C. Wainwright
Precigen price target lowered to $6 from $10 at H.C. Wainwright
07/05/22 Stifel
Precigen subsidiary sale relieves convertible debt overhang, says Stifel
NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

07/11/22 H.C. Wainwright
Nurix Therapeutics price target lowered to $54 from $60 at H.C. Wainwright
07/08/22 Stifel
Nurix Therapeutics price target lowered to $37 from $44 at Stifel
07/08/22 JPMorgan
Nurix Therapeutics price target lowered to $37 from $46 at JPMorgan
07/08/22 Baird
Nurix Therapeutics price target lowered to $32 from $41 at Baird
NUVA NuVasive
$45.25 /

+2.27 (+5.28%)

08/23/22 Piper Sandler
NuVasive selloff on bus tour comments an opportunity, says Piper Sandler
08/04/22 Canaccord
NuVasive price target raised to $55 from $50 at Canaccord
08/04/22 Piper Sandler
NuVasive price target lowered to $60 from $80 at Piper Sandler
06/28/22 Stifel
Stifel cuts Orthofix target, says momentum 'faded' during Q2
AUTL Autolus Therapeutics
$2.93 /

-0.16 (-5.18%)

06/14/22 Truist
Autolus Therapeutics price target lowered to $11 from $13 at Truist
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
12/20/21 H.C. Wainwright
Autolus Therapeutics price target lowered to $11 from $13 at H.C. Wainwright
HALO Halozyme
$39.40 /

+0.855 (+2.22%)

08/10/22 Benchmark
Halozyme recent weakness a buying opportunity, says Benchmark
05/23/22 SVB Securities
Halozyme initiated with an Outperform at SVB Leerink
04/14/22 Truist
Antares Pharma downgraded to Hold from Buy at Truist
04/14/22 Raymond James
Antares Pharma downgraded to Market Perform from Strong Buy at Raymond James
IMVT Immunovant
$4.95 /

+0.06 (+1.23%)

03/30/22 Chardan
Immunovant price target lowered to $14 from $20 at Chardan
01/05/22 Chardan
Immunovant price target lowered to $20 from $22 at Chardan
12/31/21 Wells Fargo
Immunovant shares to remain range-bound in 2022, says Wells Fargo
12/08/21 Wells Fargo
Immunovant initiated with an Equal Weight at Wells Fargo
JNCE Jounce Therapeutics
$3.61 /

+0.11 (+3.14%)

08/30/22 Piper Sandler
Jounce Therapeutics price target lowered to $6 from $9 at Piper Sandler
08/05/22 H.C. Wainwright
Jounce Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
05/23/22 Piper Sandler
Jounce Therapeutics price target lowered to $9 from $17 at Piper Sandler
05/12/22 Roth Capital
Jounce Therapeutics recent pullback overdone, says Roth Capital
IDYA Ideaya Biosciences
$9.25 /

+0.01 (+0.11%)

08/16/22 Baird
Ideaya Biosciences price target lowered to $18 from $26 at Baird
08/16/22 Oppenheimer
Ideaya Biosciences price target lowered to $20 from $25 at Oppenheimer
08/15/22 Stifel
Ideaya Biosciences downgraded to Hold at Stifel after GSK waives IDE397 opt-in
08/15/22 Stifel
Ideaya Biosciences downgraded to Hold from Buy at Stifel
SYK Stryker
$210.95 /

+8.14 (+4.01%)

09/06/22 BTIG
Stryker price target lowered to $238 from $244 at BTIG
07/28/22 Edward Jones
Stryker upgraded to Buy at Edward Jones following pullback
07/28/22 Edward Jones
Stryker upgraded to Buy from Hold at Edward Jones
07/27/22 Wells Fargo
Stryker price target lowered to $237 from $286 at Wells Fargo
NPCE NeuroPace
$4.73 /

+0.01 (+0.21%)

04/05/22 Wolfe Research
NeuroPace initiated with an Outperform at Wolfe Research
01/19/22 Wells Fargo
Wells Fargo downgrades NeuroPace to Equal Weight, lowers price target to $11
01/19/22 Wells Fargo
NeuroPace downgraded to Equal Weight from Overweight at Wells Fargo
01/07/22 Morgan Stanley
NeuroPace cut to Underweight at Morgan Stanley on cloudy near-term outlook
IONS Ionis Pharmaceuticals
$43.27 /

+1.585 (+3.80%)

08/10/22 Citi
Ionis Pharmaceuticals price target raised to $28 from $26 at Citi
07/26/22 Piper Sandler
Ionis Pharmaceuticals price target raised to $58 from $55 at Piper Sandler
07/20/22 Piper Sandler
Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
07/18/22 Oppenheimer
Ionis Pharmaceuticals assumed with an Outperform at Oppenheimer
HRMY Harmony Biosciences
$45.98 /

+1.62 (+3.65%)

09/01/22 Mizuho
Harmony Biosciences recent weakness a buying opportunity, says Mizuho
08/18/22 Mizuho
Harmony Biosciences Orange Book update 'incremental negative,' says Mizuho
08/03/22 Jefferies
Jefferies downgrades Harmony Biosciences to Hold, sees limited near-term upside
08/03/22 Oppenheimer
Harmony Biosciences price target raised to $67 from $62 at Oppenheimer
WAT Waters
$302.39 /

+4.89 (+1.64%)

SYK Stryker
$210.95 /

+8.14 (+4.01%)

SWAV ShockWave Medical
$287.16 /

+12.37 (+4.50%)

SUPN Supernus
$34.11 /

+0.07 (+0.21%)

RGLS Regulus
$1.54 /

-0.04 (-2.53%)

PGEN Precigen
$2.31 /

+0.02 (+0.88%)

PEN Penumbra
$184.98 /

+20.76 (+12.64%)

ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

NUVA NuVasive
$45.25 /

+2.27 (+5.28%)

NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

NPCE NeuroPace
$4.73 /

+0.01 (+0.21%)

LEGN Legend Biotech
$43.82 /

-0.21 (-0.48%)

KYMR Kymera Therapeutics
$28.48 /

+2.555 (+9.86%)

JNCE Jounce Therapeutics
$3.61 /

+0.11 (+3.14%)

IONS Ionis Pharmaceuticals
$43.27 /

+1.585 (+3.80%)

INSP Inspire Medical
$188.51 /

+5.5 (+3.01%)

INGN Inogen
$28.45 /

+0.86 (+3.12%)

IMVT Immunovant
$4.95 /

+0.06 (+1.23%)

IDYA Ideaya Biosciences
$9.25 /

+0.01 (+0.11%)

HRMY Harmony Biosciences
$45.98 /

+1.62 (+3.65%)

HOLX Hologic
$67.72 /

+0.34 (+0.50%)

HALO Halozyme
$39.40 /

+0.855 (+2.22%)

GILD Gilead
$64.88 /

+1.45 (+2.29%)

FATE Fate Therapeutics
$27.32 /

+2.03 (+8.03%)

DGX Quest Diagnostics
$127.43 /

+2.325 (+1.86%)

BNFT Benefitfocus
$7.02 /

+0.31 (+4.62%)

AVEO Aveo Pharmaceuticals
$8.35 /

+0.37 (+4.64%)

AUTL Autolus Therapeutics
$2.93 /

-0.16 (-5.18%)

ABBV AbbVie
$138.72 /

+1.08 (+0.78%)

  • 12
    Aug
  • 27
    Jul
  • 16
    Dec
SYK Stryker
$210.95 /

+8.14 (+4.01%)

GILD Gilead
$64.88 /

+1.45 (+2.29%)

ABBV AbbVie
$138.72 /

+1.08 (+0.78%)

SYK Stryker
$210.95 /

+8.14 (+4.01%)

SWAV ShockWave Medical
$287.16 /

+12.37 (+4.50%)

SUPN Supernus
$34.11 /

+0.07 (+0.21%)

PEN Penumbra
$184.98 /

+20.76 (+12.64%)

ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

NUVA NuVasive
$45.25 /

+2.27 (+5.28%)

NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

LEGN Legend Biotech
$43.82 /

-0.21 (-0.48%)

KYMR Kymera Therapeutics
$28.48 /

+2.555 (+9.86%)

JNCE Jounce Therapeutics
$3.61 /

+0.11 (+3.14%)

IDYA Ideaya Biosciences
$9.25 /

+0.01 (+0.11%)

HRMY Harmony Biosciences
$45.98 /

+1.62 (+3.65%)

HOLX Hologic
$67.72 /

+0.34 (+0.50%)

HALO Halozyme
$39.40 /

+0.855 (+2.22%)

GILD Gilead
$64.88 /

+1.45 (+2.29%)

FATE Fate Therapeutics
$27.32 /

+2.03 (+8.03%)

DGX Quest Diagnostics
$127.43 /

+2.325 (+1.86%)

AVEO Aveo Pharmaceuticals
$8.35 /

+0.37 (+4.64%)

ABBV AbbVie
$138.72 /

+1.08 (+0.78%)

WAT Waters
$302.39 /

+4.89 (+1.64%)

SYK Stryker
$210.95 /

+8.14 (+4.01%)

GILD Gilead
$64.88 /

+1.45 (+2.29%)

ABBV AbbVie
$138.72 /

+1.08 (+0.78%)

Over a month ago
Conference/Events
Hologic participates in a conference call with JPMorgan » 13:25
08/16/22
08/16
13:25
08/16/22
13:25
HOLX

Hologic

$72.27 /

-1.19 (-1.62%)

JPMorgan Life Science…

JPMorgan Life Science Tools & Diagnostics Analyst Woodring holds a conference call with CEO MacMillan on August 16 at 2 pm hosted by JPMorgan. Webcast Link

ShowHide Related Items >><<
HOLX Hologic
$72.27 /

-1.19 (-1.62%)

HOLX Hologic
$72.27 /

-1.19 (-1.62%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
HOLX Hologic
$72.27 /

-1.19 (-1.62%)

HOLX Hologic
$72.27 /

-1.19 (-1.62%)

Conference/Events
Hologic participates in a conference call with JPMorgan » 04:55
08/16/22
08/16
04:55
08/16/22
04:55
HOLX

Hologic

$73.46 /

+0.45 (+0.62%)

JPMorgan Life Science…

JPMorgan Life Science Tools & Diagnostics Analyst Woodring holds a conference call with CEO MacMillan on August 16 at 2 pm hosted by JPMorgan.

ShowHide Related Items >><<
HOLX Hologic
$73.46 /

+0.45 (+0.62%)

HOLX Hologic
$73.46 /

+0.45 (+0.62%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
HOLX Hologic
$73.46 /

+0.45 (+0.62%)

HOLX Hologic
$73.46 /

+0.45 (+0.62%)

Conference/Events
Hologic participates in a conference call with JPMorgan » 00:28
08/13/22
08/13
00:28
08/13/22
00:28
HOLX

Hologic

$72.98 /

+0.94 (+1.30%)

JPMorgan Life Science…

JPMorgan Life Science Tools & Diagnostics Analyst Woodring holds a conference call with CEO MacMillan on August 16 at 2 pm hosted by JPMorgan.

ShowHide Related Items >><<
HOLX Hologic
$72.98 /

+0.94 (+1.30%)

HOLX Hologic
$72.98 /

+0.94 (+1.30%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
HOLX Hologic
$72.98 /

+0.94 (+1.30%)

HOLX Hologic
$72.98 /

+0.94 (+1.30%)

Hot Stocks
Court affirms ruling barring Minerva from challenging Hologic's patent rights » 18:13
08/11/22
08/11
18:13
08/11/22
18:13
HOLX

Hologic

$72.02 /

-0.2 (-0.28%)

, NERV

Minerva

$3.35 /

-0.12 (-3.46%)

Hologic (HOLX) announced…

Hologic (HOLX) announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a 2018 district court ruling that barred Minerva (NERV) from challenging the validity of the patent rights it assigned to Hologic. "We are pleased that the U.S. Court of Appeals has once again ruled in our favor. This important decision confirms that good faith and fair dealing apply to transactions involving patents and provides greater certainty for companies like Hologic who acquire innovative technologies in order to provide physicians and their patients with the latest solutions," said Essex Mitchell, President of Hologic's GYN Surgical Solutions Division. In 2015, Hologic sued Minerva alleging that the company's endometrial ablation system infringes patents acquired by Hologic through its 2004 purchase of Novacept, the developer of the NovaSure endometrial ablation system for abnormal uterine bleeding. The suit alleged that four years after Hologic's acquisition of Novacept, a former Novacept executive founded Minerva and developed and commercialized an endometrial ablation device using the patented technology that was acquired by Hologic in the Novacept transaction. In 2018, a Delaware district court found Minerva liable for patent infringement and barred the company's invalidity defenses under assignor estoppel. A jury awarded Hologic $4.8M in damages for Minerva's infringement. This decision by the U.S. Court of Appeals is the latest decision in Hologic's favor on this matter. In 2019, the Federal Circuit affirmed the district court ruling on infringement and assignor estoppel. In 2021, the U.S. Supreme Court clarified the scope of assignor estoppel and, on remand, the Federal Circuit again ruled in Hologic's favor, holding that Minerva's invalidity challenge contradicted multiple representations made by the Novacept executive, including in assigning the patent. With the Federal Circuit decision, Minerva must now pay Hologic more than $7M in damages, which includes the $4.8M in damages originally awarded plus post-trial damages and interest.

ShowHide Related Items >><<
NERV Minerva
$3.35 /

-0.12 (-3.46%)

HOLX Hologic
$72.02 /

-0.2 (-0.28%)

HOLX Hologic
$72.02 /

-0.2 (-0.28%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
NERV Minerva
$3.35 /

-0.12 (-3.46%)

03/04/22 H.C. Wainwright
Minerva price target lowered to $5 from $10 at H.C. Wainwright
NERV Minerva
$3.35 /

-0.12 (-3.46%)

HOLX Hologic
$72.02 /

-0.2 (-0.28%)

HOLX Hologic
$72.02 /

-0.2 (-0.28%)

Earnings
Hologic raises FY22 EPS view to $5.79-$5.84 from $5.45-$5.65 » 16:06
07/27/22
07/27
16:06
07/27/22
16:06
HOLX

Hologic

$70.96 /

+0.87 (+1.24%)

Consensus $5.56. Raises…

Consensus $5.56. Raises Fy22 revenue view to $4.75B-$4.78B from $4.6B-$4.7B, consensus $4.68B

ShowHide Related Items >><<
HOLX Hologic
$70.96 /

+0.87 (+1.24%)

HOLX Hologic
$70.96 /

+0.87 (+1.24%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
HOLX Hologic
$70.96 /

+0.87 (+1.24%)

HOLX Hologic
$70.96 /

+0.87 (+1.24%)

Earnings
Hologic sees Q4 EPS 60c-65c, consensus 61c » 16:05
07/27/22
07/27
16:05
07/27/22
16:05
HOLX

Hologic

$70.96 /

+0.87 (+1.24%)

Sees Q4 revenue…

Sees Q4 revenue $840M-$870M, consensus $870M

ShowHide Related Items >><<
HOLX Hologic
$70.96 /

+0.87 (+1.24%)

HOLX Hologic
$70.96 /

+0.87 (+1.24%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
HOLX Hologic
$70.96 /

+0.87 (+1.24%)

HOLX Hologic
$70.96 /

+0.87 (+1.24%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.